References
Key articles
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019 Jun 18;139(25):e1082-143.Full text Abstract
Laufs U, Parhofer KG, Ginsberg HN, et al. Clinical review on triglycerides. Eur Heart J. 2020 Jan 1;41(1):99-109c.Full text Abstract
Berglund L, Brunzell JD, Goldberg AC, et al; Endocrine Society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012 Sep;97(9):2969-89.Full text Abstract
Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 Aug 31;78(9):960-93.Full text Abstract
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-88.Full text Abstract
Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017 Apr;23(Suppl 2):1-87.Full text Abstract
Reference articles
1. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007 Apr 10;176(8):1113-20.Full text Abstract
2. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019 Jun 18;139(25):e1082-143.Full text Abstract
3. Sandesara PB, Virani SS, Fazio S, et al. The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocr Rev. 2019 Apr 1;40(2):537-57.Full text Abstract
4. Sandhu S, Al-Sarraf A, Taraboanta C, et al. Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study. Lipids Health Dis. 2011 Sep 11;10:157.Full text Abstract
5. Laufs U, Parhofer KG, Ginsberg HN, et al. Clinical review on triglycerides. Eur Heart J. 2020 Jan 1;41(1):99-109c.Full text Abstract
6. Hegele RA, Ginsberg HN, Chapman MJ, et al.; European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014 Aug;2(8):655-66.Full text Abstract
7. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - an integrated approach to mechanisms and disorder. N Engl J Med. 1967;276:273-281. Abstract
8. Berglund L, Brunzell JD, Goldberg AC, et al; Endocrine Society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012 Sep;97(9):2969-89.Full text Abstract
9. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 Aug 31;78(9):960-93.Full text Abstract
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) - executive summary. JAMA. 2001 May 16;285(19):2486-97. Abstract
11. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-88.Full text Abstract
12. Hegele RA, Borén J, Ginsberg HN, et al. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes Endocrinol. 2020 Jan;8(1):50-67. Abstract
13. Simha V. Management of hypertriglyceridemia. BMJ. 2020 Oct 12;371:m3109. Abstract
14. Brahm A, Hegele RA. Hypertriglyceridemia. Nutrients. 2013 Mar 22;5(3):981-1001.Full text Abstract
15. Tóth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: the national health and nutrition examination survey 2003-2006. J Clin Lipidol. 2012 Jul-Aug;6(4):325-30. Abstract
16. Toth PP, Fazio S, Wong ND, et al. Risk of cardiovascular events in patients with hypertriglyceridaemia: a review of real-world evidence. Diabetes Obes Metab. 2020 Mar;22(3):279-89.Full text Abstract
17. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011 May 24;123(20):2292-333.Full text Abstract
18. Lewis GF, Xiao C, Hegele RA. Hypertriglyceridemia in the genomic era: a new paradigm. Endocr Rev. 2015 Feb;36(1):131-47.Full text Abstract
19. Goldberg RB, Chait A. A comprehensive update on the chylomicronemia syndrome. Front Endocrinol (Lausanne). 2020 Oct 23;11:593931.Full text Abstract
20. Chait A, Eckel RH. The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment. Ann Intern Med. 2019 May 7;170(9):626-34. Abstract
21. Rosenson RS, Hegele RA, Gotto AM Jr. Integrated measure for atherogenic lipoproteins in the modern era: risk assessment based on apolipoprotein B. J Am Coll Cardiol. 2016 Jan 19;67(2):202-4.Full text Abstract
22. Burnett JR, Hooper AJ, Hegele RA. Remnant cholesterol and atherosclerotic cardiovascular disease risk. J Am Coll Cardiol. 2020 Dec 8;76(23):2736-9.Full text Abstract
23. Sniderman AD, Pencina M, Thanassoulis G. ApoB. Circ Res. 2019 May 10;124(10):1425-7.Full text Abstract
24. Babirak SP, Iverius PH, Fujimoto WY, et al. Detection and characterization of the heterozygote state for lipoprotein lipase deficiency. Arteriosclerosis. 1989 May-Jun;9(3):326-34.Full text Abstract
25. Stahel P, Xiao C, Hegele RA, et al. The atherogenic dyslipidemia complex and novel approaches to cardiovascular disease prevention in diabetes. Can J Cardiol. 2018 May;34(5):595-604. Abstract
26. Dron JS, Hegele RA. Genetics of hypertriglyceridemia. Front Endocrinol (Lausanne). 2020 Jul 24;11:455.Full text Abstract
27. Dron JS, Wang J, Cao H, et al. Severe hypertriglyceridemia is primarily polygenic. J Clin Lipidol. 2019 Jan - Feb;13(1):80-8.Full text Abstract
28. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. Arterioscler Thromb. 1992 Aug;12(8):911-9. Abstract
29. Goldberg IJ, Ibrahim N, Bredefeld C, et al. Ketogenic diets, not for everyone. J Clin Lipidol. 2021 Jan-Feb;15(1):61-7.Full text Abstract
30. Abbasi F, McLaughlin T, Lamendola C, et al. High carbohydrate diets, triglyceride-rich lipoproteins, and coronary heart disease risk. Am J Cardiol. 2000 Jan 1;85(1):45-8. Abstract
31. Gjuladin-Hellon T, Davies IG, Penson P, et al. Effects of carbohydrate-restricted diets on low-density lipoprotein cholesterol levels in overweight and obese adults: a systematic review and meta-analysis. Nutr Rev. 2019 Mar 1;77(3):161-80.Full text Abstract
32. Klop B, do Rego AT, Cabezas MC. Alcohol and plasma triglycerides. Curr Opin Lipidol. 2013 Aug;24(4):321-6. Abstract
33. Golden A, Kessler C. Obesity and genetics. J Am Assoc Nurse Pract. 2020 Jul;32(7):493-6. Abstract
34. Jennings J, Faselis C, Yao MD. NAFLD-NASH: an under-recognized epidemic. Curr Vasc Pharmacol. 2018;16(3):209-13. Abstract
35. Katsiki N, Mikhailidis DP, Banach M. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. Expert Opin Pharmacother. 2019 Nov;20(16):2007-17. Abstract
36. Oh J, Hegele RA. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis. 2007 Dec;7(12):787-96. Abstract
37. Waters DD, Hsue PY. Lipid abnormalities in persons living with HIV infection. Can J Cardiol. 2019 Mar;35(3):249-59. Abstract
38. Arnaldi G, Scandali VM, Trementino L, et al. Pathophysiology of dyslipidemia in Cushing's syndrome. Neuroendocrinology. 2010;92 (Suppl 1):86-90.Full text Abstract
39. Salazar A, Mana J, Pinto X, et al. Low levels of high-density lipoprotein-cholesterol in patients with active sarcoidosis. Atherosclerosis. 1998 Jan;136(1):133-7. Abstract
40. Escárcega RO, García-Carrasco M, Fuentes-Alexandro S, et al. Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease. Autoimmun Rev. 2006 Nov;6(1):48-53. Abstract
41. Aviram M, Carter A, Brook JG, et al. Chylomicronaemia in multiple myeloma. Scand J Haematol. 1985 May;34(5):436-41. Abstract
42. Markell MS, Friedman EA. Hyperlipidemia after organ transplantation. Am J Med. 1989 Nov;87(5N):61-67N. Abstract
43. Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am. 1994 Jan;78(1):117-41. Abstract
44. Goldberg AS, Hegele RA. Severe hypertriglyceridemia in pregnancy. J Clin Endocrinol Metab. 2012 Aug;97(8):2589-96.Full text Abstract
45. Brahm AJ, Hegele RA. Chylomicronaemia: current diagnosis and future therapies. Nat Rev Endocrinol. 2015 Jun;11(6):352-62. Abstract
46. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007 Jul 18;298(3):299-308.Full text Abstract
47. Huet F, Roubille C, Roubille F. Is hypertriglyceridemia atherogenic? Curr Opin Lipidol. 2019 Aug;30(4):291-9.Full text Abstract
48. Hubert HB, Feinleb M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983 May;67(5):968-77.Full text Abstract
49. LeBlanc S, Coulombe F, Bertrand OF, et al. Hypertriglyceridemic waist: a simple marker of high-risk atherosclerosis features associated with excess visceral adiposity/ectopic fat. J Am Heart Assoc. 2018 Apr 13;7(8):e008139.Full text Abstract
50. Saeed S, Waje-Andreassen U, Nilsson PM. The association of the metabolic syndrome with target organ damage: focus on the heart, brain, and central arteries. Expert Rev Cardiovasc Ther. 2020 Sep;18(9):601-14. Abstract
51. Toth PP, Philip S, Hull M, et al. Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: a large administrative retrospective analysis. Clin Cardiol. 2019 Oct;42(10):908-13.Full text Abstract
52. Kaltoft M, Langsted A, Nordestgaard BG. Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study. Eur Heart J. 2020 Jun 21;41(24):2288-99.Full text Abstract
53. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017 Apr;23(Suppl 2):1-87.Full text Abstract
54. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. September 2016 [internet publication].Full text
55. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11-22.Full text Abstract
56. Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019 Sep 17;140(12):e673-91.Full text Abstract
57. Chaudhry R, Viljoen A, Wierzbicki AS. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome. Expert Rev Clin Pharmacol. 2018 Jun;11(6):589-98. Abstract
58. Borén J, Packard CJ, Taskinen MR. The roles of apoc-III on the metabolism of triglyceride-rich lipoproteins in humans. Front Endocrinol (Lausanne). 2020 Jul 28;11:474.Full text Abstract
59. Hegele RA, Tsimikas S. Lipid-lowering agents. Circ Res. 2019 Feb;124(3):386-404.Full text Abstract
60. Gouni-Berthold I, Alexander VJ, Yang Q, et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021 May;9(5):264-75. Abstract
61. Witztum JL, Gaudet D, Freedman SD, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019 Aug 8;381(6):531-42.Full text Abstract
62. Nurmohamed NS, Dallinga-Thie GM, Stroes ESG. Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia. Expert Rev Cardiovasc Ther. 2020 Jun;18(6):355-61.Full text Abstract
63. Berberich AJ, Ziada A, Zou GY, et al. Conservative management in hypertriglyceridemia-associated pancreatitis. J Intern Med. 2019 Dec;286(6):644-50.Full text Abstract
64. Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021 Aug;37(8):1129-50.Full text Abstract
65. Veterans Health Administration; Department of Defense. VA/DoD clinical practice guideline for the management of dyslipidemia for cardiovascular risk reduction. June 2020 [internet publication].Full text
66. Rosenzweig JL, Bakris GL, Berglund LF, et al. Primary prevention of ASCVD and T2DM in patients at metabolic risk: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019 Jul 31 [Epub ahead of print].Full text Abstract
67. Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 Dec;45(12):3754-832.Full text Abstract
68. Academy of Nutrition and Dietetics (American Dietetic Association). Disorders of lipid metabolism: evidence-based nutrition practice guideline. 2011 [internet publication].Full text
69. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. Circulation. 2011 Mar 22;123(11):1243-62.Full text Abstract
70. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update. J Am Coll Cardiol. 2011 Nov 29;58(23):2432-46.Full text Abstract
Use of this content is subject to our disclaimer